> top > docs > PMC:7544934 > spans > 142-1909 > annotations

PMC:7544934 / 142-1909 JSONTXT

Annnotations TAB JSON ListView MergeView

LitCovid_Glycan-Motif-Structure

Id Subject Object Predicate Lexical cue
T1 1368-1371 https://glytoucan.org/Structures/Glycans/G00057MO denotes LDN
T2 1368-1371 https://glytoucan.org/Structures/Glycans/G31736BK denotes LDN
T3 1480-1483 https://glytoucan.org/Structures/Glycans/G00057MO denotes LDN
T4 1480-1483 https://glytoucan.org/Structures/Glycans/G31736BK denotes LDN
T5 1530-1533 https://glytoucan.org/Structures/Glycans/G00057MO denotes LDN
T6 1530-1533 https://glytoucan.org/Structures/Glycans/G31736BK denotes LDN
T7 1689-1692 https://glytoucan.org/Structures/Glycans/G00057MO denotes LDN
T8 1689-1692 https://glytoucan.org/Structures/Glycans/G31736BK denotes LDN

LitCovid-PD-HP

Id Subject Object Predicate Lexical cue hp_id
T1 538-552 Phenotype denotes cytokine storm http://purl.obolibrary.org/obo/HP_0033041
T2 637-656 Phenotype denotes respiratory failure http://purl.obolibrary.org/obo/HP_0002878
T3 1001-1016 Phenotype denotes cytokines storm http://purl.obolibrary.org/obo/HP_0033041

LitCovid-PubTator

Id Subject Object Predicate Lexical cue tao:has_database_id
30 431-461 Gene denotes Angiotensin-Converting Enzyme2 Gene:59272
31 463-467 Gene denotes ACE2 Gene:59272
32 748-754 Gene denotes ERK1/2 Gene:5595
33 800-806 Gene denotes ERK1/2 Gene:5595
34 949-954 Gene denotes Spike Gene:43740568
35 966-970 Gene denotes ACE2 Gene:59272
36 1027-1033 Gene denotes ERK1/2 Gene:5595
37 1404-1410 Gene denotes ERK1/2 Gene:5595
38 1515-1519 Gene denotes ACE2 Gene:59272
39 0-47 Species denotes Severe Acute Respiratory Syndrome Coronavirus 2 Tax:2697049
40 49-59 Species denotes SARS-CoV-2 Tax:2697049
41 247-260 Species denotes coronaviruses Tax:11118
42 262-272 Species denotes SARS-CoV-2 Tax:2697049
43 708-716 Species denotes patients Tax:9606
44 938-948 Species denotes SARS-CoV-2 Tax:2697049
45 1202-1212 Chemical denotes naltrexone MESH:D009271
46 1356-1366 Chemical denotes Naltrexone MESH:D009271
47 1699-1709 Chemical denotes naltrexone MESH:D009271
48 77-96 Disease denotes Coronavirus Disease MESH:D018352
49 98-106 Disease denotes COVID-19 MESH:C000657245
50 470-490 Disease denotes SARS-CoV-2 infection MESH:C000657245
51 637-656 Disease denotes respiratory failure MESH:D012131
52 673-695 Disease denotes multiple organ failure MESH:D009102
53 699-707 Disease denotes COVID-19 MESH:C000657245
54 1611-1632 Disease denotes coronavirus infection MESH:D018352
55 1643-1651 Disease denotes toxicity MESH:D064420

LitCovid-sentences

Id Subject Object Predicate Lexical cue
T7 0-147 Sentence denotes Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is the cause of Coronavirus Disease (COVID-19) that has resulted in a global pandemic.
T8 148-235 Sentence denotes At the time of writing, approximately 16.06 million cases have been reported worldwide.
T9 236-469 Sentence denotes Like other coronaviruses, SARS-CoV-2 relies on the surface Spike glycoprotein to access the host cells, mainly through the interaction of its Receptor Binding Domain (RBD) with the host receptor Angiotensin-Converting Enzyme2 (ACE2).
T10 470-553 Sentence denotes SARS-CoV-2 infection induces a profound downstream pro-inflammatory cytokine storm.
T11 554-717 Sentence denotes This release of the pro-inflammatory cytokines is underpinning lung tissue damage, respiratory failure, and eventually multiple organ failure in COVID-19 patients.
T12 718-869 Sentence denotes The phosphorylation status of ERK1/2 is positively correlated with virus load and ERK1/2 inhibition suppressed viral replication and viral infectivity.
T13 870-1125 Sentence denotes Therefore, molecular entities able to interfere with binding of the SARS-CoV-2 Spike protein to ACE2, or damping hyperinflammatory cytokines storm, blocking ERK1/2 phosphorylation have a great potential to inhibit viral entry along with viral infectivity.
T14 1126-1336 Sentence denotes Herein, we report that the FDA-approved non-peptide opioid antagonist drug, naltrexone suppresses high fat/LPS induced pro-inflammatory cytokine release both from macrophage cells and Adipose Tissue Macrophage.
T15 1337-1421 Sentence denotes Moreover, Low Dose Naltrexone (LDN) also showed its activity as an ERK1/2 inhibitor.
T16 1422-1529 Sentence denotes Notably, virtual docking and simulation data also suggest LDN may disrupt the interaction of ACE2 with RBD.
T17 1530-1633 Sentence denotes LDN may be considered as a target as the treatment and (or) adjuvant therapy for coronavirus infection.
T18 1634-1767 Sentence denotes Clinical toxicity measurements may not be required for LDN since naltrexone was previously tested and is an approved drug by the FDA.